Xofluza Dosage/Direction for Use

Posology: Treatment of influenza: A single dose of baloxavir marboxil should be taken as soon as possible within 48 hours of symptom onset.
Post-exposure prophylaxis of influenza: A single dose of baloxavir marboxil should be taken as soon as possible within 48 hours following close contact with an individual known or suspected to have influenza (see Pharmacology: Pharmacodynamics under Actions).
Adults and adolescents (≥ 12 years of age): The recommended oral dose of baloxavir marboxil depending on body weight is shown in Table 5. (See Table 5.)

Click on icon to see table/diagram/image

There are no clinical data on the use of a repeat dose of baloxavir marboxil for the treatment of uncomplicated influenza or for post-exposure prophylaxis in any one influenza season.
Special populations: Elderly (≥ 65 years): No dosage adjustment is required (see Pharmacology: Pharmacokinetics under Actions).
Renal impairment: No dose adjustment is required in patients with renal impairment (see Pharmacology: Pharmacokinetics under Actions).
Hepatic impairment: No dose adjustment is required for patients with mild or moderate hepatic impairment (Child-Pugh class A or B). The safety and efficacy of baloxavir marboxil has not been established in patients with severe hepatic impairment (Child-Pugh class C).
Paediatric population: The safety and efficacy of baloxavir marboxil in children aged < 12 years has not been established.
Method of administration: Oral use. The tablets should be taken with water.
Xofluza may be taken with or without food (see Pharmacology: Pharmacokinetics under Actions).
Xofluza should not be taken with products that contain polyvalent cations such as laxatives, antacids or oral supplements containing iron, zinc, selenium, calcium or magnesium (see Interactions).